Regeneron Pharmaceuticals, Inc.

Regeneron Pharmaceuticals discovers, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company operates across multiple therapeutic areas, with flagship products including Eylea and Eylea HD for eye diseases such as wet age-related macular degeneration and diabetic macular edema; Dupixent for atopic dermatitis, asthma, and allergic conditions; Libtayo for cutaneous squamous cell carcinoma and other cancers; and Kevzara for rheumatoid arthritis. Regeneron also develops monoclonal and bispecific antibodies through collaborations with partners like Sanofi, and maintains early-stage partnerships in gene editing and RNA interference technologies. The company employs proprietary VelociSuite technologies, including VelocImmune, to accelerate drug development by utilizing genetically humanized mice to produce optimized fully human antibodies. Founded in 1988 and headquartered in Tarrytown, New York, Regeneron serves patients across oncology, immunology, ophthalmology, and cardiovascular disease markets globally.